HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jnumed.108.052654v1 49/8/1395    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Hay, I. D. Articles by Sisson, J. C. PubMed Articles by Hay, I. D. Articles by Sisson, J. C.

Perspective: The Case Against Radioiodine Remnant Ablation in Patients with Well-Differentiated Thyroid Carcinoma

¹ Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota; ² Division of Nuclear Medicine and Molecular Imaging, Stanford University Hospital and Clinics, Stanford, California; and ³ Division of Nuclear Medicine, Department of Radiology, University of Michigan Health System, Ann Arbor, Michigan

Correspondence: For correspondence or reprints contact: James C. Sisson, Division of Nuclear Medicine, Department of Radiology, Hospital B1 G505D, University of Michigan Health System, Ann Arbor, MI 48109-0028. E-mail: jsisson{at}umich.edu

We take issue with the stance that postoperative radioiodine remnant ablation should be applied ubiquitously as adjuvant therapy in patients with well-differentiated thyroid carcinoma. In this article, we state the reasons that we believe a compelling case can be made against ablation in most patients.

Key Words: endocrinology • oncology • radionuclide therapy • ablation • radioiodine • thyroid carcinoma

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]